Platelet transfusion refractoriness: how do I diagnose and manage?

Area of Science:

• Immunology
• Hematology
• Transfusion Medicine

Background:

• Platelet refractoriness increases bleeding risk in thrombocytopenic patients.
• Nonimmune causes are common, but immune-mediated refractoriness requires specific management.
• Antibodies to human leukocyte antigen (HLA) class I molecules are the primary cause of immune-based platelet refractoriness.

Observation:

• Antibodies to human leukocyte antigen (HLA) class I molecules are the primary cause of immune-based platelet refractoriness.
• Antibodies targeting platelet-specific antigens are less frequent causes.

Findings:

• Patients can be supported with crossmatch-compatible or HLA-matched/compatible platelet units.
• When a perfect HLA match is unavailable, antibody specificity prediction identifies compatible platelet units by avoiding known antigens targeted by patient antibodies.

Implications:

• Accurate diagnosis and targeted platelet transfusion strategies are crucial for managing immune-based platelet refractoriness.
• Utilizing antibody specificity prediction improves the selection of compatible platelet units, optimizing patient outcomes and reducing bleeding risks.